DR. DOPING

Instructions

Logo DR. DOPING

Instructions / Instruction for use: MUSE

I want this, give me price

Dosage Form:urethral suppositories

Active substance:

Alprostadil * (Alprostadilum)

ATX

C01EA01 Alprostadil

Pharmacotherapeutic groups:

Antiplatelet agents

Prostaglandins, thromboxanes, leukotrienes and their antagonists

Angioprotectors and proofreaders microcirculation

Regulators potency

The nosological classification (ICD-10)

F52.2 Lack of genital response: Secondary impotence; hyposexuality; Impotence; Impotence on the basis of neurasthenia; Impotence against the background of functional nervous disorders; Impotence of different origin; Violation potency; erectile Dysfunction; potency Disorders; erectile dysfunction; Erectile dysfunction of various origins; Lack of erection; The weakening of potency; The weakening of sexual activity; The weakening of erection; Lowering the male potency; Sexual disorders in men; Sexual dysfunction; Weak potency; Reduced potency; Reduced potency; erectile disfunction; Erectile dysfunction, neurogenic

Composition and release form

1 comprises a urethral suppository of alprostadil 125, 250, 500 or 1000 mcg; in packages, complete with an applicator, in box 6 or 1 pc.

Characteristics

Drug transurethral system for single use.

Pharmacology

Mode of action - improves microcirculation in the penis.

It causes vasodilation in the vascular pool cavernous and spongy bodies.

Pharmacodynamics

Expansion of the cavernous arteries and vessels of the trabecular smooth muscle corpus cavernosum leads to rapid blood flow and dilation of lacunar spaces in the cavernous bodies; since expanded corporal sinusoids are compressed tunica, venous outflow through the vessels located under the tunica, difficult and develops an erection (the so-called "corporal venookklyuzionny mechanism"). It has systemic effects: vasodilatory, antiagregatsionnym stimulates the smooth muscles of the intestines and alvus.

Pharmacokinetics

Once intraurethral administration (suppository dissolution and residual urine) about 80% of the injected dose quickly - within 10 minutes - with absorbed mucous membranes of the urethra in the spongy body. Part of the administered dose enters the cavernous body (via collateral vessels), the remainder - in the venous network of the perineum; caught in the central venous circulation drug almost completely eliminated from the systemic circulation of the lungs; T1 / 2 is 0.5-10 minutes. The injection site, mainly in the lung (60-90%) is rapidly metabolised to form various derivatives of PG E1. Pharmacological effect occurs within 5-10 minutes after administration, and continues for about 30-60 min.

Indications of the drug MUSE

Erectile disfunction.

Contraindications

Hypersensitivity, violations of the anatomy of the penis (urethral stricture, pronounced curvature and others.), Balanitis, urethritis (acute, chronic); sickle cell anemia (also for suspicion), thrombocytopenia, polycythemia, multiple myeloma, venous thrombosis (including predisposition), increased blood viscosity.

Side effects

Pain in the penis, urethra, testicles, pain in the pelvis, urethral bleeding (or spotting), hypotension, dizziness, headache, rare - lasting (4-6 hours or more) erection.

Interaction

With simultaneous use of anticoagulants increases the risk of bleeding.

Dosage and Administration

Intraurethral, via the applicator introduced into the urethra after urination. Dose picked individually, the recommended initial - 125-250 micrograms once; If necessary dose gradually increase (or decrease) to achieve an erection sufficient for sexual intercourse. The maximum frequency of application - not more than two systems for 24 hours.

Overdose

Symptoms: hypotension, prolonged pain in the penis, persistent erection (6 hours or more), irreversible deterioration of erectile function. Treatment: symptomatic.

Precautionary measures

Dose selection should be carried out under the supervision of a physician, at the same time controlled by the state of the cardiovascular system and the possible emergence of prolonged erections (4 hours or more). If you assign the background of anticoagulants in patients with impaired blood clotting system it is recommended to evaluate the risk-benefit application (because of possible risk of bleeding). During treatment it is necessary to use an adequate method of contraception female partners of childbearing age.

Special instructions

May experience a burning sensation and itching in the vagina of a woman partner.

Storage conditions of MUSE

In the fridge at a temperature of 2-8 ° C.

Keep out of the reach of children.

Shelf life of MUSE

2 years.

Do not use beyond the expiration date printed on the package.